Articles From: Ultimate Selected to Present “Awesome New Technologies for HR” at the 2014 HR Technology Conference & Expo to Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults


Ultimate Software (Nasdaq: ULTI), a leading cloud provider of people management solutions, announced today that its new UltiPro Talent Acquisition solutions have been selected among the annual HR Technology ® Conference & Exposition’s “Awesome New Technologies for HR,” and will be featured in a general session at the conference on Thursday, October 9 at 1:30 p.m. at the Mandalay Bay Resort and Casino in Las Vegas.
Sign-up for Ultimate Selected to Present “Awesome New Technologies for HR” at the 2014 HR Technology Conference & Expo investment picks
Ultimate Software (Nasdaq: ULTI), a leading cloud provider of people management solutions, today announced its participation in a number of presentations at the 17th Annual HR Technology® Conference and Exposition, which will be held October 7-10 at Mandalay Bay Resort and Casino in Las Vegas.
Sign-up for Ultimate Software Announces Executive Presentations at 2014 HR Technology Conference investment picks
Ultimate Software (Nasdaq: ULTI), a leading cloud provider of people management solutions, announced today that it has delivered numerous enhancements to its HCM solution in the UltiPro Spring 2014 release, including a new compensation management product, additional talent analytics that help identify top talent, and the general availability of its new UltiPro Recruiting solution, first announced in October 2013.
Sign-up for Ultimate Software Enables Companies to Make More Effective Compensation Decisions with New Compensation Management Solution investment picks
Ultimate Software (Nasdaq:ULTI), a leading cloud provider of people management solutions, showed its new onboarding solution to attendees of the 2014 HR Technology® Conference, held October 7-10 at Mandalay Bay Resort and Casino in Las Vegas.
Sign-up for Ultimate Software Previews New Onboarding Solution at the 2014 HR Technology Conference investment picks
2014/7/21
Ultra Clean reports revenues at high end of guidance and exceeds EPS guidance for quarter on strong margin performance.
Sign-up for Ultra Clean Reports Second Quarter 2014 Financial Results investment picks
HAYWARD, Calif.
Sign-up for Ultra Clean to Announce Second Quarter 2014 Results investment picks
HAYWARD, Calif.
Sign-up for Ultra Clean to Announce Second Quarter 2014 Results investment picks
Ultra Petroleum Announces Executive Leadership Transition Canada NewsWire HOUSTON , July 15, 2014 /CNW/ -- Ultra Petroleum Corp.
Sign-up for Ultra Petroleum Announces Executive Leadership Transition investment picks
HOUSTON , July 15, 2014 /PRNewswire/ -- Ultra Petroleum Corp.
Sign-up for Ultra Petroleum Announces Executive Leadership Transition investment picks
HOUSTON , Aug.
Sign-up for Ultra Petroleum Announces Pinedale Acquisition investment picks
Ultra Petroleum Announces Pinedale Acquisition Canada NewsWire HOUSTON , Aug.
Sign-up for Ultra Petroleum Announces Pinedale Acquisition investment picks
HOUSTON , July 31, 2014 /PRNewswire/ -- Ultra Petroleum Corp.
Sign-up for Ultra Petroleum Announces Second Quarter And First Half 2014 Financial And Operating Results investment picks
HOUSTON , Sept.
Sign-up for Ultra Petroleum Corp. Announces $700 Million Offering of Senior Notes investment picks
Ultra Petroleum Corp.
Sign-up for Ultra Petroleum Corp. Announces $700 Million Offering of Senior Notes investment picks
Ultra Petroleum Corp.
Sign-up for Ultra Petroleum Corp. Announces Closing of Pinedale Acquisition investment picks
HOUSTON , Sept.
Sign-up for Ultra Petroleum Corp. Announces Closing of Pinedale Acquisition investment picks
Ultra Petroleum Corp.
Sign-up for Ultra Petroleum Corp. Announces Pricing of $850 Million Senior Note Offering investment picks
HOUSTON , July 31, 2014 /PRNewswire/ -- Ultra Petroleum Corp .
Sign-up for Ultra Petroleum Corp. To Webcast Second Quarter 2014 Results investment picks
2014/10/7
Ultra-wealthy “millennials,” those born between 1982-2000, are idealistic about the uses of their wealth, but say they are generally aligned with the values of their parents.
Sign-up for Ultra-Wealthy “Millennials” Are Idealistic, But Not Alienated; Challenge Stereotype of the “Idle Rich” investment picks
2014/9/19
NanoTech Entertainment (OTC Pink: NTEK ), a pioneer in bringing state-of-the-art television experiences to consumers, announced today that it UltraFlix will be demonstrated at 3 events in 10 major markets including Los Angeles, Dallas and Chicago.
Sign-up for UltraFlix Network Tours Ten Major Markets for Customer Demonstrations investment picks
NOVATO, Calif., July 14, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the closing of its public offering of 2,319,951 shares of common stock at a price to the public of $40.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 302,602 additional shares of common stock.
Sign-up for Ultragenyx Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares investment picks
NOVATO, Calif., July 1, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, announced the first patient screened and enrolled in the Phase 2 study of the human monoclonal anti-FGF23 antibody KRN23 (UX023) in pediatric patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
Sign-up for Ultragenyx Announces Initiation of a Phase 2 Study of KRN23 for Pediatric X-Linked Hypophosphatemia in the US and EU investment picks
NOVATO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts.
Sign-up for Ultragenyx Announces Pricing of Public Offering of Common Stock investment picks
NOVATO, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has commenced an underwritten public offering of 2,017,349 shares of its common stock.
Sign-up for Ultragenyx Announces Proposed Public Offering of Common Stock investment picks
NOVATO, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation of results from a multiple-dose study, conducted by Kyowa Hakko Kirin Pharma, Inc. (KKP), of the investigational anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH). XLH is an inherited metabolic bone disease characterized by short stature, skeletal deformities, bone pain, fractures, and muscle weakness.
Sign-up for Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Ultimate Selected to Present “Awesome New Technologies for HR” at the 2014 HR Technology Conference & Expo to Ultragenyx Announces Results From Phase 1/2 Study of KRN23 in X-linked Hypophosphatemia in Adults
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices